USE OF LOWER PROSTATE SPECIFIC ANTIGEN CUTOFFS FOR PROSTATE CANCER SCREENING IN BLACK AND WHITE MEN
- 1 November 1998
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 160 (5) , 1734-1738
- https://doi.org/10.1016/s0022-5347(01)62395-4
Abstract
Conclusions Black race was an independent predictor of prostate cancer even at lower PSA cutoffs (2.6 to 4.0 ng./ml.). Although the positive predictive value for cancer detection was relatively high in black men, long-term outcomes studies are necessary to determine whether the use of lower PSA cutoffs would result in favorable shifts in cancer stage and grade, and a reduction in racial differences in prostate cancer mortality rates.Keywords
This publication has 13 references indexed in Scilit:
- RACIAL DIFFERENCES IN OPERATING CHARACTERISTICS OF PROSTATE CANCER SCREENING TESTSJournal of Urology, 1997
- Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurementsJAMA, 1997
- PROSTATE-SPECIFIC ANTIGEN AS A SCREENING TEST FOR PROSTATE CANCERUrologic Clinics of North America, 1997
- Prostate Cancer Incidence and Mortality Rates among White and Black MenEpidemiology, 1997
- Racial Differences in a Prostate Cancer Screening StudyJournal of Urology, 1996
- Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black MenNew England Journal of Medicine, 1996
- Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery systemPublished by American Medical Association (AMA) ,1995
- Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screeningPublished by American Medical Association (AMA) ,1995
- A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancerPublished by American Medical Association (AMA) ,1995
- Prevalence and Pathological Extent of Prostate Cancer in Men with Prostate Specific Antigen Levels of 2.9 to 4.0 NG./ML.Journal of Urology, 1993